EQS-News: Evotec and Novo Nordisk join the Technology Partners for Zelltherapien der Nächsten Generation

Hamburg, September 26, 2024:
Evotec SE (Frankfurter Wertpaperbörse: EVT, SDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) has the opportunity to become an external partner with new Nordisk technology in the Bereich Zelltherapie eingangs.

Sowohl Evotec has developed as Novo Nordisk a comprehensive expertise and a strategic focus in the development of stem-based therapy. Both devices buy with the development progressive technologies a “ready-to-use” therapy product of the next generation for the clinical development and a wider potential commercial effect.

In the framework of the partnership, Novo Nordisk is supporting the technology development activities and Evotec’s F&E facility in Göttingen, Germany, as well as the certified production facility for cell therapies in Modena, Italy, are providing financing. Novo Nordisk is offering the opportunity to have exclusive rights to the treatment of the partnership’s inheritance for a predefined therapeutic treatment. Evotec is benefiting from the F&E financing, a non-offensive action that makes the Meilenstein and Lizenzzahlungen possible.

Dr. Cord Dohrmann, Chief Scientific Officer von Evotec, said: “Zelltherapies have proven their worth as one of the most effective treatments and possibilities of the disease, through which the functioning of health can be improved. Stem-zell-based Zelltherapies are one of the most common treatments, one of the therapies that are based on machine and mass-cut, “ready-made” treatment with affordable costs. Joint venture with Novo Nordisk is with its vision, innovative and resilient technology that has the potential to fully expand the therapeutic basis therapy. “

Dr. Joachim Fruebis, Corporate Vice President, Cell Therapy R&D at Novo Nordisk, says: “If we have a Kräfte with Evotec in the bundle, there is a Zelltherapie-Initiative that we can use. This partnership is one of the most reliable, root-based Spitzentherapies that helps patients to be effective. While the combination no longer works, the foundation for maintaining the Durchbrüche in the Weiterentwicklung of Zelltherapieën is abolished. These investments offer enormous potential, and if they are expanded, the fortifications will be carried out.”

About Zelltherapy at Evotec
Zelltherapie, one of the most common treatments in regenerative medicine, provides for fehlende or functional functions in treating a patient during healing, which can consist of different stems – from a spender, from patient’s own material or from stem cells. The stem zellforschung has an incomprehensible experience that enables a high-quality treatment for the only therapy. Equal time reduces the differentiation of zelltherapies with a validity of the risks of contaminating treatments, which is obtained in addition to the abreichung of spender or patient material.

Evotec has developed a Grundlage industrial platform for inducible pluripotent stem cells (“iPSCs”), a proprietary high-potency and high-throughput Zelltherapie. The Evotec initiative has proprietary and partnership types, which are in the practice of a wide range of indications, supporting diabetes, oncology, cardiology and ophthalmology.

About Evotec SE
Evotec is a scientific group with a unique business model, a high-end medicine for research, for the induction and for the patient who can find his machine. The multimodal platform of the company offers a unique innovative combination of technologies, data and scientific approach for the research, development and production of first-in-class and best-in-class pharmaceutical products. Evotec offers partnerships and solutions for pipeline co-creation of all Top 20 Pharma and more than 800 biotechnology companies, academic institutions and other health and medical devices. Evotec is strategically positioned in a wide range of current medical indications active, including neurology, oncology as well as substance and infectious diseases. Evotecs Ziel is at that time developing innovative ‘co-owned Pipeline’ innovative therapies and verlies a portfolio of more than 200 properties and co-ownership of F+E projects from the early study in the clinical Entwicklung . The quality amounts to more than 5,000 qualified people for Evotec. The state of affairs in Europe and the US offers highly synergistic technologies and services and works as a complementary Excellence cluster. Find more information on our homepage www.evotec.com and follow your Twitter account @Evotec and LinkedIn.

Future releases
This press conference has had a great influence on the first impression, which has attracted attention and the note of Evotecs working papers. Worter wie “erwarten”, “annehmen”, “schätzen”, “beabsichtigen”, “können”, “planen”, “potenziell”, “sollen”, “abzielen”, “würde”, as well as Abwandlungen dieser Wörter and ähnliche became Used, a zukunftsbezogene Aussagen to identify. Solche Aussagen schließen Comments op Evotecs Erwartungen für Umsätze, Konzern-EBITDA und unverpartnerte F+E-Aufwendungen ein. These cutbacks are based on the information that Evotec was able to provide at the time of production, as well as on observations and adjustments, which Evotec has set out to provide at this time of production. The guidelines that exist can no longer be intended with certainty. These exceptional situations may occur and pose a risk of one of the Annahmen and Schätzungen, which are inherent to insecurity and independence, whereby the control by Evotec may lie. Evotec has not used the lighting necessary to remove the settings in the manual of the Evotec verification or new insights, conditions or settings, or to update or revise these externally.

For more information you can say:

Median

Gabriele Hansen
SVP Head of Global Corporate Communications
[email protected]

Hinnerk-rohwedder
Director of Global Corporate Communications
[email protected]

Investor Relations

Volker Brown
EVP Head of Global Investor Relations & ESG
[email protected]